A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Completed · Phase 2 · NCT06373146
Conditions: Obesity
At a glance
- Research payments reported, 2025
- $11.6M
- U.S. investigators named
- 23
- Sites paid
- 16
- Planned or actual enrollment
- 392
About the trial
- Sponsor
- Eli Lilly and Company (with Regeneron Pharmaceuticals)
- Tested
- Tirzepatide (drug), Mibavademab (drug), Tirzepatide-Placebo (drug), Mibavademab-Placebo (drug)
- Dates
- Started 2024-04-24; completion 2026-04-02
- Results posted
- Not yet
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
From ClinicalTrials.gov, last updated 2026-05-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $11.6M in research payments for this study in 2025 (42 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Guzman, M.D. Internal Medicine · Los Angeles, CA
- David L. Guzman, D.P.M. Podiatrists · Napa, CA
- Robert A. Jenders Internal Medicine · Torrance, CA
- Ruth E. Kavcioglu, MD Family Medicine · Northridge, CA
- Bonnie S. Kimmel, M.D. Endocrinology & Diabetes · Walnut Creek, CA
- Elly R. Lee, MD Psychiatry · Irvine, CA
- Mark T. Leibowitz, M.D. Internal Medicine · Long Beach, CA
- Jeffrey S. Overcash, MD Emergency Medicine · Chula Vista, CA
- Dennis Tsang, MD Hospitalist · Huntington Park, CA
- Julie D. Vu, M.D. Internal Medicine · South El Monte, CA
- David Butuk, MD Family Medicine · Meridian, ID
- James P. Maynard, M.D. Neurology · Fort Thomas, KY
- Adil A. Fatakia, M.D. ENT (Otolaryngology) · Marrero, LA
- Scott P. Striplin, M.D. OB-GYN (Obstetrics & Gynecology) · Covington, LA
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Michael J. Lillestol, M.D. Internal Medicine · Fargo, ND
- Michael A. Hassman, DO Family Medicine · Berlin, NJ
- Robert E. Dunn, MD Cardiac Electrophysiology · Cleveland, OH
- Julio Rosenstock, M.D. Endocrinology & Diabetes · Dallas, TX
- Lloyd H. Stegemann, MD General Surgery · Corpus Christi, TX
- Damaris Vega, MD Endocrinology & Diabetes · Houston, TX
- Gaylon Kipp, MD Family Medicine · Bellevue, WA
- Nazia H. Rahman, M.D. Pediatrics · Bellevue, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $2.5M
- Northwest Clinical Research Center $1.5M
- Irvine Center for Clinical Research Inc $1.3M
- Solaris Clinical Research LLC $1.2M
- Sociedad Espanola De Medicina De La Adolescencia $1.2M
- South Texas Clinical Research $1.1M
- Lillestol Research LLC $959,649
- Juno Research LLC $660,836
- Cti Holdings Inc DBA Community Research Management Associates Inc $603,541
- Tandem Clinical Research,llc $344,070
- Hassman Research Institute $290,563
- Andrew J Lewin Med DBA National Rsrch Institute $783
- Mehrdad Kevin Ariani MD $676
- Advocare Berlin Medical Associates $570
- Cti-Crc $116
- Cleveland Clinic, OH $66
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.